President Donald Trump signed a sweeping executive order on 18 April 2026 directing federal agencies to fast-track the review ...

Pelage Pharmaceuticals enters late-stage trials with PP405, a topical gel that "awakens" hair follicles. See why Google Ventures is betting on this startup.

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are ...

In a major shift for federal drug policy, President Donald Trump signed an executive order on Saturday aimed at accelerating ...

The president’s executive order is intended to accelerate research into the compounds’ efficacy in treating mental health ...

The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged ...

Explore how evolving obesity research is shaping trial design, with a focus on precision, reproducibility, and clinical ...

Discover common misconceptions in renal and hepatic impairment studies and how expert teams navigate complexity in drug development.

Psyence Biomedical (PBM) stock exploded 203% on April 16, 2026, following White House ibogaine executive order news and ...

The field of exercise science has increasingly recognized the multifaceted benefits of physical activity as both a preventive and therapeutic tool across ...

Dana-Farber Cancer Institute researchers will present more than 50 studies at the American Association for Cancer Research ...